Weight Loss Metabolic

Retatrutide

The next-generation metabolic peptide — a triple-action name everyone's watching.

What is it?

Retatrutide is one of the most exciting names in the metabolic peptide world — a multi-receptor peptide studied for appetite and metabolic health. It represents the newest wave of metabolic research and is in huge demand among people following this space closely.

Why people choose it

One of the most in-demand metabolic peptides
A next-generation, multi-receptor design
Popular for appetite and body-composition goals
Available in multiple sizes, including a convenient pen

What is it used for?

Appetite and weight goals
Blood sugar support
Metabolic health
Body composition

How it works

Retatrutide is designed to act on more than one of the gut-hormone pathways involved in appetite and metabolism. This multi-pathway approach is what makes it the talk of the metabolic community.

Good to know

Offered in 10mg, 20mg and an easy-to-use 30mg pen.
Part of the same family as Semaglutide and Tirzepatide.
One of the most requested metabolic products right now.

Available options

10mg €10.00

20mg €10.00

30mg (pen) €10.00

Every option can be ordered directly through the cart above.

Research use only — not for human or veterinary consumption.

Dosage protocol

Reconstitution maths, titration steps and syringe draw volumes as published by peptidedosages.com.

Reference information only — not medical advice and not a prescription. Speak to a qualified professional before using any peptide.

Route: Subcutaneous injection
Cycle length: 24–48 weeks

Mixing (reconstitution)

Vial	Add BAC water	Concentration	1 unit (0.01 ml)
10 mg	1 mL	10.0 mg/mL	100 mcg
20 mg	2 mL	10.0 mg/mL	100 mcg
30 mg	3 mL	10.0 mg/mL	100 mcg

Dosing schedule

Standard Frequency: Once weekly

Phase	Dose	Units	Volume
Weeks 1–4	2 mg	20 units	0.20 mL
Weeks 5–8	4 mg	40 units	0.40 mL
Weeks 9–12	6 mg	60 units	0.60 mL
Weeks 13+	8 mg	80 units	0.80 mL

Advanced Frequency: Once weekly

Phase	Dose	Units	Volume
Weeks 1–4	2 mg	20 units	0.20 mL
Weeks 5–8	4 mg	40 units	0.40 mL
Weeks 9–12	8 mg	80 units	0.80 mL
Weeks 13+	12 mg split into 2 injections at different sites	120 units	1.20 mL

Storage

Powder (unmixed): −20 °C
After mixing: 2–8 °C
Use within: weeks
Avoid freeze–thaw cycles

Technique

Clean the vial stopper and the skin with an alcohol swab and let both air-dry.
Pinch a skinfold and insert the needle at 45–90° into the subcutaneous tissue.
Do not aspirate for subcutaneous injections — inject slowly and steadily.
Wait 5–10 seconds before withdrawing, then apply gentle pressure. Do not rub the site.
Rotate sites systematically — abdomen (at least 5 cm from the navel), thighs and upper arms — to avoid lipohypertrophy.
Use a new sterile 28–31 G insulin syringe every time and dispose of it in a sharps container.

Reported side effects

Mild-to-moderate nausea
Vomiting
Diarrhoea

Safety & evidence

Side effects cluster during dose escalation, are dose-dependent and transient; gradual titration reduces them.
Phase 2 trials reported roughly 22–24% average weight loss at 48 weeks on 8–12 mg, and HbA1c reductions of 1.3–2.0% in type 2 diabetes.
No severe hypoglycaemia or serious treatment-related adverse events were reported.
Not FDA-approved — available for research purposes only.

Figures transcribed from peptidedosages.com: /single-peptide-dosages/retatrutide-10-mg-vial-dosage-protocol/